The therapeutic application of Marbocyl 2% is applied in addressing bacterial infections across various therapeutic domains, generally supporting the management of conditions characterized by heightened symptoms.

The medicine is commonly used to help manage acute respiratory infections (like pneumonia in young cattle and pigs), complicated skin and soft-tissue infections (such as deep pyoderma), and urogenital infections (including UTIs and postpartum syndromes like MMA in sows). The medication is commonly used when symptomatic management is needed in more challenging clinical contexts or when conditions present as deep-seated and difficult to manage.

It is considered relevant for easing symptoms linked to recurrent or deep-seated bacterial issues.

This use covers symptom clusters that may appear suddenly or intensify over time, such as high fever and difficulty breathing, or symptoms involving severe inflammation and pus formation. The medicine is relevant for managing symptom clusters and the associated irritative processes and is relevant for easing the overall symptom load during these episodes, contributing to maintaining functional stability.

Quick Fact: Used in managing symptoms related to Persistent Inflammation

Regulatory References

1. Veterinary Medicines Directorate (VMD) Summary of Product Characteristics

Eligibility Map: Who can and cannot use Marbocyl 2% — Official Regulatory Information

The eligibility criteria for Marbocyl 2% (Marbofloxacin 20 mg/ml solution for injection) are strictly defined by regulatory documents for its target species, cattle and pigs.

Eligibility Scope

Eligibility Classifications (High-Level)

Resulting Eligibility Structure

Official eligibility statements mandate that the drug must not be given to animals with known allergies to the quinolone class of antibiotics. Furthermore, use is only permitted in the approved species—cattle and pigs—when the infectious agent is confirmed to be susceptible to the medicine. Administration during pregnancy or lactation is permitted only following a professional evaluation, while use is strictly prohibited in animals producing milk for human consumption .

: Based on a review of national veterinary medicines regulatory documents (SPC/Prescribing Information). : Based on a review of official contraindications and special warnings listed in regulatory documents.

Interaction Scope: Officially Documented Substances

Marbocyl 2% (Marbofloxacin) has officially documented interactions with several medicinal product categories and substances. The main interacting agents include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), the airway dilator Theophylline, Cyclosporine, and oral products containing divalent or trivalent cations such as aluminium, calcium, iron, or magnesium.

Interaction Classifications and Restrictions

The interaction profile is divided into two principal categories: pharmacokinetic (exposure-altering) and pharmacodynamic (risk augmentation). Regulatory labeling defines specific constraints for co-administration.

Official Interaction Statements

• Cation-Containing Products: Co-administration with oral products containing cations, such as certain antacids or mineral supplements, can result in a reduced bioavailability of Marbofloxacin due to a pharmacokinetic interaction affecting absorption. A timing separation between doses is therefore necessary to mitigate this effect.
• Theophylline: Co-administration results in increased plasma concentrations of Theophylline, indicating a pharmacokinetic interaction due to altered clearance.
• NSAIDs: A specific regulatory restriction notes that the use of Marbofloxacin with NSAIDs should be avoided in dogs with a history of seizures due to a documented pharmacodynamic risk of increased neurological side effects.
• Cyclosporine: Co-use may exacerbate the nephrotoxicity associated with Cyclosporine.

Connection to the Overall Interaction Profile

Official regulatory documents define the product’s interaction structure by detailing substances that modify Marbofloxacin absorption, medicines that require adjustment due to altered exposure, and agents associated with a defined additive toxicity risk. This structure establishes the required restrictions and mandatory conditions for co-administration as documented in the label.

Marbofloxacin Targets Core Bacterial DNA Replication

Marbocyl 2% contains the active component Marbofloxacin, a synthetic antibiotic that functions as an inhibitor. It binds specifically to two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By blocking the function of these enzymes, the drug prevents processes required for bacterial survival, specifically the essential supercoiling, strand-separation, and repair of the bacterial chromosome.

Mechanistic Cascade Leads to Bactericidal Effect

The inhibition of these DNA-managing enzymes causes irreversible double-strand breaks in the bacterial genome. This damage overwhelms the bacteria's repair capacity, initiating a concentration-dependent bactericidal effect, leading to the lysis and death of the susceptible bacterial cell. This mechanism results in the death of susceptible bacterial populations due to DNA fragmentation.

Selective Action on Bacterial Enzymes

The mechanism of action relies on the significant structural difference between the target bacterial topoisomerases and the corresponding enzymes in host animal cells. This selectivity causes the effect to be focused solely on the pathogen, preserving the integrity of the host's cellular processes.

How Marbocyl 2% is Used: Administration Guidelines

The administration of Marbocyl 2% Solution for Injection involves specific routes, dosing, and procedural constraints based on the target animal population. This medicine is formulated as a 2% w/v sterile aqueous solution for injection, containing 20 mg of marbofloxacin per ml.

Administration Scope

Special Procedural Conditions

Administration procedures include specific constraints to ensure proper delivery. When treating pigs, the volume of injection must be limited to a maximum of 10 ml at any single injection site. Furthermore, guidelines recommend the use of a draw-off needle during the preparation phase to minimize the risk of particulate contamination from repeated puncturing of the vial's septum.

Marbocyl 2%: Recent Clinical Evidence

Evidence for Use in Acute Respiratory Infections

Research examining this medicine for use in acute respiratory infections (such as Bovine Respiratory Disease in calves and A. pleuropneumoniae in pigs) primarily consists of Randomized Controlled Field Trials (RCTs). These studies were used in research exploring how symptoms change over time and in studies examining short-term or episodic symptom patterns across the observed animal populations. Researchers focused on measuring specific outcomes, including the measurement of a defined clinical cure rate and monitoring changes in visible signs of illness, such as fever and difficulty breathing. The findings from these trials describe patterns observed when the medicine was compared against active control treatments, often structured as non-inferiority studies.

Research on Other Indicated Conditions

Studies for the use of Marbocyl 2% in sows affected by Metritis-Mastitis-Agalactia (MMA) syndrome include Clinical Trials cited in regulatory documentation and specific Pharmacokinetic (PK) studies. These PK studies focused on the drug's absorption and distribution to key tissues like the uterus.

For acute mastitis in lactating cows, Randomized Field Trials are used in research examining the medicine's effect against specific Gram-negative bacteria, particularly E. coli. The research describes limitations noting that findings related to acute mastitis apply only to specific bacterial types, but the evidence structure does not support use against the acute forms of the disease caused by Gram-positive bacteria.

Research Scope and Uncertainty

The research monitored responses over defined time intervals, often extending up to three or four weeks post-treatment. Comparative evidence is lacking for large-scale placebo-controlled studies, which limits the ability to directly characterize the medicine's profile in isolation. Furthermore, long-term effects and the incidence of future, unrelated episodes are not fully established by the existing regulatory research.

Key Studies & References Veterinary Medicines Directorate (VMD) Summary of Product Characteristics (SPC) for Marbocyl 2%

Common questions about Marbocyl 2% (FAQ)

Q: How long does it take for Marbocyl 2% to start working?

Studies and official product information indicate that the active component, marbofloxacin, is quickly and readily absorbed after the injection, with high bioavailability. This rapid absorption allows the medicine to be distributed to most tissues quickly, which supports its intended action against susceptible bacteria, according to regulatory information.

Q: What is the legal withdrawal period for meat after using Marbocyl 2%?

According to the official product information, a legally required waiting period is defined before animals treated with Marbocyl 2% can be used for food production. The withdrawal period for meat and offal is 6 days for pre-ruminant calves and 4 days for pigs.

Q: What do I do if my animal has an allergic reaction to the injection?

Regulatory documents list hypersensitivity reactions as very rare adverse events. The official safety information notes that in the event of an observed adverse reaction, the owner is advised to contact a veterinarian.

Q: How should I store Marbocyl 2% after it has been opened?

Once the vial is punctured for the first time, Marbocyl 2% has an official in-use shelf-life of 28 days. The product is required to be stored at a temperature below 25 C and protected from light throughout this period, as stated in the product label.

Q: Can Marbocyl 2% be used in adult cattle or only in calves?

The official regulatory documents specify the target species for this medicine. It is indicated for use only in pigs and in pre-ruminating calves up to 100 kg body weight.

How to Store and Dispose of Marbocyl 2%

The storage and disposal of Marbocyl 2% Solution for Injection must comply strictly with the conditions stated in regulatory labeling.

Official Storage Requirements

The product must be stored at a temperature below 25 C and protected from light. To ensure protection from light, the container must be kept in the outer carton.

Stability and Disposal

The medicine has a defined in-use shelf-life of 28 days following the first dose withdrawal. Any remaining product must be discarded after this period.

All unused veterinary medicinal product and associated waste must be disposed of in accordance with local regulations. A specific environmental restriction also requires that manure and slurry from treated animals should not be spread on the same area of land in successive years.